CONMED
CNMD
207 hedge funds and large institutions have $2.18B invested in CONMED in 2018 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 91 increasing their positions, 51 reducing their positions, and 26 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 51
46% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 26
8% more capital invested
Capital invested by funds: $2.01B → $2.18B (+$166M)
6% more funds holding
Funds holding: 196 → 207 (+11)
0.63% less ownership
Funds ownership: 98.55% → 97.92% (-0.63%)
71% less call options, than puts
Call options by funds: $640K | Put options by funds: $2.22M
Top Buyers
| 1 |
BlackRock
New York
|
+$21.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$12.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.9M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$10.3M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$8.93M |
Top Sellers
CNMD Hedge Fund Activity: Q3 2018 in Review
207 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q3 2018, worth a combined $2.18B — up 8.2% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new CNMD positions and 26 closed out — a net gain of 12 holders — while 91 added to existing stakes and 51 trimmed.
The largest buyer was BlackRock, adding an estimated $21.2M. The largest seller was Scopia Capital Management, cutting an estimated $40.2M.
- 207 institutional investors held CONMED (CNMD) as of Q3 2018, up from 196 in Q2 2018.
- Funds reported $2.18B of CONMED stock for Q3 2018, up 8.2% quarter-over-quarter.
- 38 funds opened new CONMED positions in Q3 2018 and 26 closed out, a net change of +12 holders.
- The largest CONMED buyer in Q3 2018 was BlackRock, an estimated $21.2M added.
- The largest CONMED seller in Q3 2018 was Scopia Capital Management, an estimated $40.2M sold.
Based on aggregated 13F filings for Q3 2018.